Cempra Inc (CEMP.OQ)

CEMP.OQ on NASDAQ Stock Exchange Global Select Market

34.12USD
4 May 2015
Change (% chg)

-- (--)
Prev Close
$34.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
260,290
52-wk High
$41.63
52-wk Low
$8.51

CEMP.OQ

Chart for CEMP.OQ

About

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,471.51
Shares Outstanding(Mil.): 43.59
Dividend: --
Yield (%): --

Financials

  CEMP.OQ Industry Sector
P/E (TTM): -- 188.47 40.23
EPS (TTM): -1.81 -- --
ROI: -70.31 -0.64 15.26
ROE: -94.12 -2.50 16.08
Search Stocks

Cempra's lead oral antibiotic meets main goal in late-stage trial

- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.

05 Jan 2015

UPDATE 2-Cempra's lead oral antibiotic meets main goal in late-stage trial

Jan 5 - Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.

05 Jan 2015

Cempra's lead oral antibiotic meets main goal in late-stage trial

Jan 5 - Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial.

05 Jan 2015

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

12 Dec 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks